Thomas Misko has had over 25 years of experience in pharmaceutical R&D. His expertise includes both small molecules and biologics and spans from early Discovery to Phase 2 POC. After receiving his Bachelor of Science degree in Biological Sciences from Indiana University, he received his doctorate in Biochemistry from Johns Hopkins University. As a postdoctoral fellow (Stanford) in the laboratory of Dr. Eric Shooter, he purified and cloned the low affinity NGFR (p75). Joining Searle-Monsanto (St. Louis), he contributed to/led several projects to discover/develop potential therapeutics for Inflammation and Neuroinflammation. During his tenure in St. Louis (Pharmacia, Pfizer), Tom co-discovered the activation of cyclooxygenase by NO and led a group that developed sensitive assays to monitor iNOS (inducible nitric oxide synthase) activity in vivo and in vitro by quantifying nitrites/nitrates as well as nitrated proteins. These assays were instrumental in the discovery and clinical development of selective inhibitors for iNOS through enabling the monitoring of target engagement in the clinic. Toms collaborations with academia (e.g., Drs. Anne Cross, David Holtzman, L.S. Lohmander) helped to characterize the role of iNOS in diseases such as MS, AD and arthritis (RA, OA) in which free radical-mediated injury appears to contribute to disease pathology. His work in neuroscience, inflammation and neuroinflammation has resulted in over 60 peer-reviewed publications.
As a Scientific Director in Translational Medicine at Takeda, Tom led teams monitoring biomarkers in CSF and in plasma to assess target engagement and coverage for potential disease-modifying and symptomatic therapies in schizophrenia, epilepsy and AD. Dr. Misko is currently a Senior Scientific Director in Translational Neuroscience at AbbVie where he has devoted his efforts to advancing AbbVies growing portfolio in Neurology focused on disease-modifying therapeutics and neurorestorative therapies in MS, AD, Stroke and PD.